Balyasny Asset Management’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $119M | Buy |
650,046
+42,093
| +7% | +$7.76M | 0.15% | 140 |
|
|
2025
Q4 | $107M | Sell |
607,953
-626,196
| -51% | -$102M | 0.14% | 166 |
|
|
2025
Q3 | $173M | Buy |
1,234,149
+402,244
| +48% | +$54.4M | 0.22% | 83 |
|
|
2025
Q2 | $104M | Buy |
831,905
+45,686
| +6% | +$5.69M | 0.16% | 143 |
|
|
2025
Q1 | $108M | Buy |
786,219
+740,390
| +1,616% | +$106M | 0.18% | 118 |
|
|
2024
Q4 | $7.01M | Buy |
+45,829
| New | +$7.73M | 0.01% | 1113 |
|
|
2024
Q3 | – | Sell |
-394,887
| Closed | -$82.6M | – | 2745 |
|
|
2024
Q2 | $91.5M | Buy |
+394,887
| New | +$85.8M | 0.16% | 144 |
|
|
2024
Q1 | – | Sell |
-317,302
| Closed | -$82.1M | – | 2625 |
|
|
2023
Q4 | $82.1M | Buy |
317,302
+86,891
| +38% | +$21.3M | 0.15% | 155 |
|
|
2023
Q3 | $59.2M | Buy |
230,411
+170,423
| +284% | +$45.6M | 0.12% | 224 |
|
|
2023
Q2 | $17.1M | Sell |
59,988
-179,407
| -75% | -$53.4M | 0.04% | 587 |
|
|
2023
Q1 | $66.6M | Buy |
239,395
+188,012
| +366% | +$52M | 0.17% | 150 |
|
|
2022
Q4 | $14.2M | Sell |
51,383
-124,782
| -71% | -$35.2M | 0.04% | 604 |
|
|
2022
Q3 | $47M | Buy |
176,165
+152,859
| +656% | +$32.5M | 0.14% | 168 |
|
|
2022
Q2 | $4.75M | Sell |
23,306
-144,870
| -86% | -$29.6M | 0.02% | 962 |
|
|
2022
Q1 | $35.4M | Buy |
168,176
+86,932
| +107% | +$18.9M | 0.11% | 234 |
|
|
2021
Q4 | $19.5M | Buy |
81,244
+34,709
| +75% | +$8.92M | 0.07% | 422 |
|
|
2021
Q3 | $13.2M | Sell |
46,535
-91,744
| -66% | -$30.1M | 0.05% | 472 |
|
|
2021
Q2 | $47.9M | Buy |
138,279
+48,659
| +54% | +$14.7M | 0.23% | 92 |
|
|
2021
Q1 | $25.1M | Buy |
89,620
+54,485
| +155% | +$14.7M | 0.12% | 211 |
|
|
2020
Q4 | $8.6M | Sell |
35,135
-118,123
| -77% | -$30.5M | 0.05% | 475 |
|
|
2020
Q3 | $43.5M | Buy |
+153,258
| New | +$42.7M | 0.32% | 62 |
|
|
2020
Q1 | – | Sell |
-129,669
| Closed | -$39.4M | – | 1170 |
|
|
2019
Q4 | $38.5M | Buy |
129,669
+115,873
| +840% | +$32.2M | 0.23% | 116 |
|
|
2019
Q3 | $3.21M | Sell |
13,796
-106,661
| -89% | -$24.8M | 0.02% | 631 |
|
|
2019
Q2 | $28.2M | Buy |
120,457
+97,034
| +414% | +$22.4M | 0.18% | 161 |
|
|
2019
Q1 | $5.54M | Sell |
23,423
-83,143
| -78% | -$26.2M | 0.04% | 547 |
|
|
2018
Q4 | $32.1M | Buy |
106,566
+100,039
| +1,533% | +$31.9M | 0.23% | 115 |
|
|
2018
Q3 | $2.31M | Sell |
6,527
-39,178
| -86% | -$13.5M | 0.01% | 934 |
|
|
2018
Q2 | $13.3M | Sell |
45,705
-394,455
| -90% | -$111M | 0.06% | 404 |
|
|
2018
Q1 | $121M | Sell |
440,160
-107,449
| -20% | -$33.4M | 0.5% | 26 |
|
|
2017
Q4 | $174M | Buy |
547,609
+385,130
| +237% | +$124M | 0.55% | 20 |
|
|
2017
Q3 | $50.9M | Sell |
162,479
-99,166
| -38% | -$29.4M | 0.2% | 129 |
|
|
2017
Q2 | $71M | Buy |
261,645
+215,029
| +461% | +$56.9M | 0.29% | 75 |
|
|
2017
Q1 | $12.7M | Sell |
46,616
-48,210
| -51% | -$13.6M | 0.06% | 409 |
|
|
2016
Q4 | $26.9M | Sell |
94,826
-353,399
| -79% | -$105M | 0.14% | 199 |
|
|
2016
Q3 | $140M | Buy |
448,225
+204,573
| +84% | +$60.6M | 0.81% | 11 |
|
|
2016
Q2 | $58.9M | Buy |
243,652
+41,685
| +21% | +$11M | 0.38% | 56 |
|
|
2016
Q1 | $52.6M | Buy |
201,967
+25,013
| +14% | +$6.61M | 0.31% | 76 |
|
|
2015
Q4 | $54.2M | Sell |
176,954
-35,847
| -17% | -$10.3M | 0.38% | 64 |
|
|
2015
Q3 | $62.1M | Sell |
212,801
-62,445
| -23% | -$20.6M | 0.46% | 47 |
|
|
2015
Q2 | $111M | Buy |
275,246
+248,336
| +923% | +$99.7M | 0.68% | 23 |
|
|
2015
Q1 | $11.4M | Sell |
26,910
-23,483
| -47% | -$9.26M | 0.09% | 321 |
|
|
2014
Q4 | $17.1M | Buy |
+50,393
| New | +$16.3M | 0.16% | 191 |
|
Other funds holding BIIB
VCM
VPM
Balyasny Asset Management's BIIB Position: Q1 2026 in Review
Balyasny Asset Management increased its Biogen (BIIB) stake by 6.9% in Q1 2026, buying an estimated $7.76M and bringing the position to 650,046 shares worth $119M. The position accounts for 0.15% of the portfolio, ranked #140.
Balyasny Asset Management first reported a position in BIIB in Q4 2014 and has held it in 42 quarters since. The position peaked at $174M in Q4 2017. 1,002 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.
- Balyasny Asset Management held 650,046 shares of Biogen worth $119M as of Q1 2026.
- Balyasny Asset Management bought 42,093 Biogen shares in Q1 2026, an estimated $7.76M.
- Biogen made up 0.15% of Balyasny Asset Management's portfolio in Q1 2026, its #140 holding.
- Balyasny Asset Management first reported a position in Biogen in Q4 2014 and has held it in 42 quarters since.
- Balyasny Asset Management's Biogen position peaked at $174M in Q4 2017.
- 1,002 funds tracked by Wall St. Rank held Biogen as of Q1 2026.
Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.